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Abstract
Patients with cirrhosis may experience neurologic complications, including hepatic encephalopathy. Hepatic encephalopathy
may be classified as covert (mild symptoms (e.g. lack of awareness)) or overt (moderate to severe symptoms (e.g. confusion or
coma)), and symptoms may overlap with other neurologic conditions (e.g. epilepsy, stroke). Managing hepatic encephalopathy
includes identifying and treating precipitating factors (e.g. dehydration). First-line treatment for patients with overt hepatic
encephalopathy is typically lactulose; to reduce the risk of overt hepatic encephalopathy recurrence, lactulose plus the
nonsystemic antibiotic rifaximin is recommended. Rifaximin reduced the risk of breakthrough overt hepatic encephalopathy
by 58% versus placebo over 6 months (p < 0.001; 91% of patients in each group were on concomitant lactulose). However,
neither pharmacologic hepatic encephalopathy treatment nor liver transplantation may completely reverse neurologic
impairment in patients with hepatic encephalopathy. Additional neurologic considerations for patients with cirrhosis include
preventing falls, as well as managing sleep-related issues, hyponatremia, and cerebral edema. Thus, monitoring neurologic
impairment is an important component in the management of patients with cirrhosis.
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Introduction
According to data from the National Health and Nutrition
Examination Survey (NHANES), cirrhosis affects an estimated 0.3% of US adults (1999–2010 data).1 However, some
individuals may be unaware they have cirrhosis; 68.7% of
individuals with cirrhosis included in NHANES indicated
they had not been diagnosed with the condition.1 During the
compensated phase of cirrhosis, patients are asymptomatic
and generally free of cirrhosis-related complications (e.g.
ascites, variceal bleeding, jaundice, hepatic encephalopathy
(HE));2,3 the onset of complications marks the transition to
decompensated cirrhosis.3,4 The aim of this narrative review is
to highlight several potential neurologic complications, with a
focus on HE, and other neurologic-related issues that might
arise in patients with cirrhosis at either stage of the disease.

Overt HE
1).5,6

HE is typically classified as covert or overt (Table
Because patients with covert HE do not present with clinically apparent symptoms, diagnosing covert HE (minimal

HE or modified West Haven (WH) grade 1 HE) requires specialized psychometric, neuropsychologic, or neurophysiologic testing.6 However, covert HE is associated with
decreased quality of life, increased risk for falls, and driving
impairment;7–9 falls within the previous year were predictive
of poor quality of life in patients with covert HE.10
Furthermore, covert HE is associated with development of
overt HE and increased risk of mortality.11,12
Overt HE is a common neurologic complication of cirrhosis,13 and symptoms range from lethargy and personality
changes (WH grade 2) to somnolence and confusion (WH
grade 3) to, in the most severe cases, coma (WH grade 4)
(Table 1).5,6 One study reported that patients with grade 2 HE
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Table 1. Modified West Haven criteria.5,6
Type of HE

Grade

Criteria

No HE (unimpaired)
Covert

–
Minimal

No evidence or history of HE
No clinically apparent abnormalities detected
Evidence of neurophysiological changes determined by psychometric or
neuropsychological testing
Lack of awareness, euphoria, or anxiety
Shortened attention span
Impairment of addition and subtraction
Lethargy
Disorientation for time
Personality changes
Inappropriate behavior
Somnolence to semistupor
Responsive to stimuli
Confusion
Gross disorientation
Bizarre behavior
Coma

1

Overt

2

3

4
Source: Adapted with permission from Vilstrup.6
HE: hepatic encephalopathy.

(40%) and grade 3 HE (42%) compose the majority of
patients with HE admitted to the hospital.14
Orientation to time and place are common challenges for
patients with more severe overt HE. Because WH criteria are
subjective, clinicians adapted a questionnaire used to assess outcomes in patients with traumatic brain injury for use as a modified-orientation log for evaluating patients with HE.14 The
modified-orientation log contains eight questions: five related
to time and three related to place. Scores range from 0 (no
answer or consistently answering question incorrectly, even
with cuing) to 3 (correct answer provided without cuing) for
each question, with a total score ranging from 0 to 24.14 In addition, a newer tool—the Hepatic Encephalopathy Grading
Instrument™—was developed to assess HE in clinical practice,
in conjunction with a caregiver electronic diary (Figure 1).15

Precipitating factors for HE
According to the guidelines from the American Association
for the Study of Liver Diseases (AASLD) and the European
Association for the Study of the Liver (EASL), treatment of
patients with overt HE includes considering other potential
causes of altered mental status, identifying and subsequently
treating precipitating factors, and initiating drug treatment for
overt HE.6 In a study that examined patients with cirrhosis
retrospectively and prospectively, overt HE–related hospitalization was associated with ⩾2 precipitating factors in most
patients (101 of 149 patients (67.9%) and 42 of 45 patients
(93.3%), respectively). In fact, in these studies, 18% and 47%
of patients, respectively, had ⩾4 precipitating factors.16 The
three most common precipitating factors were lactulose (an
HE treatment) nonadherence, dehydration, and constipation

in the retrospective analysis, and dehydration, acute renal
failure, and lactulose nonadherence and infections (latter two
tied for third) in the prospective analysis.16 Other precipitating factors for overt HE included use of certain medications
(e.g. opioids, benzodiazepines), electrolyte imbalances (e.g.
hypokalemia (potassium <3.5 mEq/L), hyponatremia
(sodium <130 mEq/L)), transjugular intrahepatic portosystemic shunts, gastrointestinal bleeding, and paracentesis.16
Identifying and managing all precipitating factors is an
important component of treating patients with overt HE.6,16

Potential misdiagnosis of neurologic conditions in
patients with cirrhosis
Given the overlap of some clinical symptoms across neurologic conditions, patients with overt HE might be misdiagnosed with other conditions (e.g. certain forms of epilepsy,
stroke).17,18 In one retrospective, single-center study of
patients with cirrhosis with a hospital stay, 20 of 2010
(number of patients) (1.0%) patients received an initial diagnosis of epilepsy.17 Further medical record review determined
the true prevalence of epilepsy was 0.7% (n = 15), as 3 of the
20 patients had been misdiagnosed and ultimately were found
to have HE.17 Although epilepsy in patients with cirrhosis is
rare, diagnosis of certain forms of epilepsy requires both clinical observation and electroencephalographic testing, given
the different readings in patients with epilepsy versus patients
with overt HE (Table 2).17 However, the potential for misdiagnosing epilepsy in patients with HE might be mitigated by
a complete medical history and clinical exam.17
Patients with HE might also be misdiagnosed with
stroke.18 A retrospective study found an increased risk of
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Figure 1. Hepatic Encephalopathy Grading Instrument.15

Source: Reprinted with permission from Bajaj.15
HE: hepatic encephalopathy; HEGI: Hepatic Encephalopathy Grading Instrument.
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Table 2. Features of epilepsy and HE by EEG.17
EEG feature

Epilepsy

HE

Wave activity
Wave type
Organization of waves
Reactivity to stimulation

Rhythmic
Sharp, poly sharp
Spatial temporal
None

Slow (2–3 Hz)
Fluctuating triphasic
Maximum over anterior regions
Inconsistent

HE: hepatic encephalopathy; EEG: electroencephalogram.

Figure 2. Guideline recommendations for management of patients with HE.6
HE: hepatic encephalopathy.

stroke in patients with cirrhosis versus patients without the
condition (hazard ratio (HR) = 1.8, 95% confidence interval
(CI) = 1.5–2.0).19 One case study reported on a patient with
HE who presented with neurologic symptoms compatible
with a diagnosis of stroke (i.e. right-sided hemiparesis,
right-sided sensory disturbance, Babinski sign, Chaddock
sign, impaired language skills, flapping tremors) and initially was misdiagnosed and treated on suspicion of that
condition.18 A diagnosis of HE ultimately was established
after researchers found no evidence for stroke based on
magnetic resonance imaging and angiography during an
examination, along with electroencephalographic results
consistent with HE (i.e. triphasic wave).18 The patient
received branched-chain amino acids for HE, with symptom
improvement observed.18
In addition, Wilson’s disease, a rare genetic metabolic
condition resulting in disordered copper storage, can progress from hepatic impairment to cirrhosis.20,21 The disease
also is associated with neurologic symptoms that have been
associated with HE (e.g. ataxia, dysphagia, dysarthria, parkinsonism, apathy, irritability, aggression, disinhibition).

Treatment of overt HE
Typically, first-line therapy for patients with overt HE is the
nonabsorbable disaccharide lactulose (Figure 2).6 Patients

should receive 25 mL of lactulose every 1 to 2 hours until
⩾2 soft or loose bowel movements per day are achieved;
lactulose should then be titrated to maintain 2 to 3 daily
bowel movements.6 Aspiration is a potential complication
of oral lactulose administration in patients with more severe
HE (e.g. unconscious patients); caution is warranted with
this population.6 For patients who are hospitalized and unable to swallow or are at risk of aspiration, lactulose can be
administered using a nasogastric tube6 or by enema.
However, lactulose is plagued by nonadherence. Data
from a single-center chart review of 137 patients reported
that recurrence of HE (n = 103) was associated with lactulose
nonadherence (n = 39, 37.9%) and lactulose-induced dehydration (n = 8, 7.8%; defined as >4 bowel movements per
day with dehydration and azotemia).22 Lactulose nonadherence (n = 39) was associated with gastrointestinal-related
adverse events (AEs), including diarrhea (n = 27), bloating
(n = 18), and abdominal pain (n = 16), which resulted in failure of patients to adequately self-titrate lactulose dosing.22
Furthermore, both retrospective and prospective analyses of
patients with HE reported that lactulose nonadherence was
associated with recurrence of HE in more than half of patients
examined (51.4% and 53%, respectively).16 Interestingly, the
authors also observed that 8 of 137 patients, all of whom
were adherent to treatment, developed recurrent HE due to
lactulose-associated dehydration (i.e. >4 bowel movements
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per day with dehydration and azotemia; new increase in
serum creatinine >1.5 mg/dL).22
Guidelines from AASLD and EASL recommend lactulose in combination with the nonsystemic antibiotic rifaximin for the prevention of HE recurrence.6 In a phase 3,
randomized, double-blind, placebo-controlled study, rifaximin 550 mg twice daily (n = 140) reduced the risk of breakthrough overt HE by 58% versus placebo (n = 159) during a
6-month period (HR = 0.42, 95% CI = 0.28–0.64, p < 0.001)
in patients with a history of recurrent overt HE (i.e. ⩾2 episodes within previous 6 months).23 Furthermore, rifaximin
significantly reduced the risk of overt HE-related hospitalization versus placebo during 6 months of treatment
(HR = 0.50, 95% CI = 0.29–0.87, p = 0.01).23 Approximately
91% of patients in either group received concomitant treatment with lactulose.23 In this 6-month study, twice-daily
rifaximin was well tolerated.23 The risk of Clostridium difficile infection with rifaximin was low: two rifaximin-treated
patients had a C. difficile infection; both had multiple risk
factors for C. difficile infection, including older age, recent
hospitalizations during which antibiotics were used, and use
of the proton-pump inhibitor pantoprazole.23
An open-label study that evaluated rifaximin for long-term
(⩾2 years) prevention of overt HE recurrence included
patients who had received placebo during the original
6-month randomized study,24 newly enrolled patients with a
history of overt HE (new-rifaximin population), and patients
who had received rifaximin during the original 6-month
randomized study (historical-rifaximin population).24 The
groups were analyzed together (all-rifaximin population) and
separately with comparison to the historical-rifaximin or historical-placebo population from the original study.24 Overall,
89.8% of patients included in the all-rifaximin population
received concomitant lactulose.24 The rates of HE-related
hospitalizations were comparable between the all-rifaximin,
new-rifaximin, and historical-rifaximin (i.e. 6-month
randomized study) populations (0.21 events/person-years of
exposure (PYE), 0.23 events/PYE, and 0.30 events/PYE,
respectively).24 Furthermore, the rates of all-cause hospitalizations in the all-rifaximin and new-rifaximin populations
were decreased compared with the historical-placebo population from the 6-month randomized study (0.45 events/PYE
and 0.44 events/PYE versus 1.30 events/PYE, respectively).24
No increase in AE rates was observed in the open-label,
long-term (⩾2 years) study; four patients in the open-label
study—all of whom had multiple risk factors for C.
difficile—developed C. difficile infection.24
Beyond reducing the risk of overt HE recurrence, rifaximin plus lactulose (n = 63) reversed HE in a significantly
higher percentage of patients experiencing an overt HE episode versus lactulose alone (n = 57) within 10 days (76% versus 44%, respectively; p = 0.004).25 Mortality was
significantly decreased with rifaximin plus lactulose compared with lactulose alone (24% versus 49.1%, respectively;
p < 0.05).25 However, 81.7% of patients included in this

study had WH grade 3 or 4 HE at baseline.25 Furthermore,
data suggest that rifaximin may reduce the risk of other complications of cirrhosis. In one study of patients treated for
HE, rifaximin plus lactulose (n = 145) was associated with a
reduction in the risk of a variety of complications of cirrhosis
versus lactulose alone (n = 276): HE recurrence (HR = 0.45,
95% CI = 0.29–0.72, p < 0.001), developing spontaneous
bacterial peritonitis (SBP; HR = 0.21, 95% CI = 0.11–0.40,
p < 0.001), variceal bleeding (HR = 0.42, 95% CI = 0.22–
0.82, p = 0.01), and mortality (HR = 0.70, 95% CI = 0.51–
0.95, p = 0.02).26
According to AASLD and EASL guidelines, neomycin
or metronidazole may be used as an alternative to lactulose
alone or lactulose plus rifaximin to treat patients with
overt HE, though data are limited.6 However, chronic use
of these two agents should be avoided because of the risk
for ototoxicity, nephrotoxicity, and neurotoxicity associated with long-term administration.6 Although polyethylene glycol 3350-electrolyte solution (PEG) is not
recommended in current guidelines,6 a randomized, single-center US study (n = 50) reported that PEG significantly improved the mean HE grade from baseline
compared with lactulose (baseline scores: 2.3 and 2.3,
respectively) within 24 hours (1.5 versus 0.7, respectively;
p = 0.002).27 For patients who received either PEG or lactulose, median time to HE resolution was 1 and 2 days,
respectively (p = 0.01).27 In this study, PEG and lactulose
were considered generally well tolerated, with no serious
AEs (PEG, n = 3; lactulose, n = 5) considered to be “definitely” or “probably” related to treatment.27
It should be noted that pharmacologic treatment of overt
HE and liver transplantation may not completely reverse
neurologic impairment in some patients.28,29 Results of a prospective study of patients with cirrhosis reported that, compared with patients without a history of HE (n = 138), those
with a history of HE (n = 36) may have persistent learning
impairments, as assessed by psychometric testing, despite
having received lactulose with or without rifaximin for HE.28
In addition, while liver transplantation is considered to
largely reverse HE impairments, some patients with a history
of HE may not experience a complete reversal of cognitive
impairment posttransplant;29 however, ongoing improvement in cognition has been observed during the first year
posttransplant.30

Additional neurologic-related issues to consider
for patients with cirrhosis
Health care providers, caregivers, and patients should be
aware of several neurologic-related issues affecting patients
with cirrhosis, including fall prevention and management of
sleep-related issues, hyponatremia, and cerebral edema.
Prevention of falls. A significantly greater percentage of
patients with cirrhosis with cognitive impairment had >1
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fall during a 1-year period (40.4%) versus patients with cirrhosis without cognitive impairment (6.2%, p < 0.001); furthermore, the group with cognitive impairment had a
significantly greater mean number of falls per patient versus
the group without cognitive impairment (0.8 versus 0.1,
p = 0.003).31 In addition, patients with cognitive impairment
had a significantly greater need for fall-related care (i.e. primary care, emergency department care, or hospitalization)
versus patients without cognitive impairment (e.g. emergency room visits, 23.8% versus 2.5%, respectively;
p < 0.001).31 In a retrospective study, intracranial hemorrhage occurred in a significantly greater percentage of
patients with cirrhosis with falls or trauma, focal neurologic
signs, or history of intracranial hemorrhage, versus patients
with altered mental status, headache, or fever (8.9% versus
0.3%, respectively; p < 0.0001).32 In patients with cirrhosis
(n = 118), falls in the previous year negatively affected
health-related quality of life (p = 0.001).33
In a population-based study (n = 3764 per group), fracture
incidence rate ratios (IRRs) versus matched controls were
significantly greater in patients with cirrhosis and HE
(IRR = 1.3, 95% CI = 1.02–1.72, p = 0.03) and patients with
cirrhosis without a history of HE (IRR = 1.6, 95% CI = 1.69–
2.05, p = 0.001).34 Cumulative 18-month fracture incidence
rates also were significantly greater for patients with cirrhosis with HE (7.1%) and without HE (7.7%) versus matched
controls (4.0%; p = 0.001 and p < 0.001, respectively).34 In a
retrospective study of US hospitalized patients with cirrhosis
(2010–2013), falls occurred in 55 of 1749 (3.1%) cirrhosisrelated hospital admissions.35 Patients who had taken benzodiazepines and antipsychotic agents were at significantly
greater risk for falls (benzodiazepines: odds ratio (OR) = 6.6,
95% CI = 3.8–11.6; antipsychotics: OR = 3.7, 95% CI = 1.9–
7.1, adjusted for HE).35 Although patients with cirrhosis
were not at significantly greater risk of experiencing a fall
compared with patients in the general hospital population,
they were more likely to experience a fall-related injury (rate
ratio = 3.4, 95% CI = 2.0–5.7, p < 0.0001).35 Thus, proactive
prevention of falls should not be overlooked in the management of patients with cirrhosis, particularly patients with
neurologic impairment (i.e. presence or history of HE).
Management of sleep-related issues. Patients with cirrhosis
may experience sleep disturbances that can negatively
impact cognitive function. In a study that compared patients
with cirrhosis with a chronic disease control group (i.e.
patients with inflammatory bowel disease), patients with cirrhosis had poorer sleep quality based on the results of the
Pittsburgh Sleep Quality Index (PSQI; global, p = 0.002;
PSQI components: sleep disturbance, p = 0.03; daytime dysfunction, p = 0.02; habitual sleep efficiency, p = 0.001; sleep
latency, p = 0.03) and, not surprisingly, experienced worsening cognitive impairment.36 For obese patients (body mass
index >30 kg/m2) with cirrhosis, obstructive sleep apnea
may be a potential cause of daytime sleepiness, rather than
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the disruption of sleep–wake cycles known to occur in
patients with overt HE.37 Thus, health care providers should
assess potential sleep disorders in patients with cirrhosis,
particularly patients who do not adequately respond to overt
HE treatment.37 Diagnosis and management of sleep-related
issues in patients with cirrhosis may improve both overall
sleep quality and cognitive outcomes; thus, a sleep medicine
consult may be considered. Caution should be exercised
when considering prescription sedatives for patients with
cirrhosis, as sedatives can precipitate HE. Furthermore, sedatives should be prescribed in low doses due to pharmacokinetic changes observed in patients with cirrhosis. For patients
with cirrhosis and insomnia, hydroxyzine can be efficacious;
for depression, trazodone may be considered.
Hyponatremia. Hyponatremia, which is common in patients
with cirrhosis, has been associated with poor outcomes (i.e.
hospitalization, mortality).38–40 Indeed, hyponatremia significantly increased the risk of mortality 7.8-fold (serum sodium
<126 mEq/L) and 6.3-fold (serum sodium <131 mEq/L) in
patients with cirrhosis on a waiting list for liver transplant.40
Furthermore, the presence of hyponatremia in patients with
cirrhosis negatively affected cognition, independent of HE.41
Correcting hyponatremia (i.e. with tolvaptan) has been
reported to improve cognition in patients with cirrhosis.42
However, due to the risk of serious liver injury, tolvaptan has
a black box warning in its label and is only available through
a Risk Evaluation and Mitigation Strategy. Given that
hyponatremia is associated with poor outcomes in patients
with cirrhosis, providers should consider monitoring sodium
levels routinely in this patient population.
Cerebral edema. Low-grade cerebral edema, detected using
magnetic resonance spectroscopy, may develop in patients with
cirrhosis and HE, and has been hypothesized to affect function
in patients with HE.43 Ammonia detoxification occurs in astrocytes, with the conversion of ammonia to glutamine.44 However, the conversion of glutamine to glutamate by glutaminase
can result in high levels of ammonia in the mitochondria of
astrocytes, potentially leading to cerebral edema in patients with
HE.44,45 In fact, low-grade cerebral edema in patients with cirrhosis has been associated with increased levels of brain glutamine.46 However, cerebral edema was reversed after treatment
(e.g. tolvaptan, lactulose and rifaximin, mannitol, hypertonic
saline) or transplantation.42,46–49 Short-term induction of high
sodium levels can be very useful in patients with hyponatremia,
but sodium correction needs to be closely monitored. Rapid correction of hyponatremia (i.e. >10 mmol/L within 24 h) has been
associated with central pontine myelinolysis.50

Conclusion
Patients with cirrhosis experience complications, including the
common neurologic complication of overt HE, which marks the
transition from the compensated to the decompensated phase of
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the disease. Overt HE has features that might overlap with other
neurologic complications observed in patients with cirrhosis.
International guidelines recommend that health care providers
who treat patients with HE consider other potential causes of
neurologic dysfunction, identify and manage the precipitating
factors for HE, and initiate a treatment regimen to reduce the
risk of overt HE recurrence (e.g. lactulose alone or with concomitant rifaximin). In a number of studies, rifaximin alone or
with concomitant lactulose reduced the risk of overt HE recurrence, HE-related hospitalizations, and development of other
complications (e.g. SBP, variceal bleeding). Because nonadherence to lactulose is associated with a risk of recurrence of HE,
patients should routinely be evaluated to determine their adherence to prescribed therapies. Cognitive impairment in patients
with cirrhosis may impact patients’ health (e.g. risk for falls),
but other neurologic-related issues can also impact cognitive
function and quality of life (e.g. sleep-related issues, hyponatremia). Neurologic complications of cirrhosis can have a profoundly negative impact on patients, and ongoing evaluation
and maintenance of ideal cognitive function is an important
component in overall management strategies.
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